𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: We will discuss with the Founder & CEO of IO Biotech what is next after this week's trial result in advanced melanoma. $IOBT

$IOBT Additionally, in Pd1-ve Cylembio+pembro showed mPFS of 16.6 months (could change slightly as data mature) looks competitive vs $REGN fianlimab +cemiplimab ph2 data which showed 9.9 months. Real chance Cylembio+pembro could become go to drug for PD1-ve group (if approved)

$IOBT Regeneron also using “Pembro” as control arm in their LAG3 combo study clinicaltrials.gov/study/NCT05352… Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

$RVMD Wells Fargo PT $67

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead. $IOBT Full video: biotechtv.com/post/io-biotec…

FDA meeting in Q3-> likely next month.

Doctors are hoping that the first nasal flu vaccine available for use at home can improve vaccination rates among people who are afraid of needles. nbcnews.com/health/cold-an…

Great interview (as always.). Thanks Brad.

Patrick is feeding 💩 to the audience.

P-value purists unable be appreciate elegance of $iobt vaccine MOA. Targets ido1 and pd1 to rev up TME. Solid proof of concept for turning cold tumors hot (data in pd1 -ve). It does it with no new safety burden. Cylembio and keytruda a viable combo option for IO responsive tumors

Makes it amenable for triple combos (since combo safety profile is identical to PD1)

LIFESCI $RVMD (OUTPERFORM,$80.00 PT): Revolutionary Medicine; Building a Wide Moat in PDAC, Pushing Inland in NSCLC, and Forming a Beachhead in CRC; 2L+ PDAC Justifies Current Valuation; Initiating OUTPERFORM, $80 PT

$IOBT some resistance here at $2.5. Still, not sure why this wouldn’t trade ar risk adjusted $500M ($6-$7) valuation since near miss was in 1L setting (larger market)

Expect mature OS HR << 0.8. They underpowered (by overestimating PFS effect) but like classic IO, I expect OS HR >> PFS HR as data matures.